INTERIM STUDY PROPOSAL 2025-112

State of Arkansas
95th General Assembly

A Bill

JMB/JMB
SENATE BILL

By: Senator C. Penzo

Filed with: Senate Committee on Public Health, Welfare, and Labor pursuant to A.C.A. §10-3-217.

For An Act To Be Entitled

AN ACT TO AUTHORIZE A LICENSED PHARMACY TO COMPOUND THERAPEUTIC PEPTIDES FOR PATIENTS WITH CERTAIN MEDICAL CONDITIONS; AND FOR OTHER PURPOSES.

Subtitle

TO AUTHORIZE A LICENSED PHARMACY TO COMPOUND THERAPEUTIC PEPTIDES FOR PATIENTS WITH CERTAIN MEDICAL CONDITIONS.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:

SECTION 1. Arkansas Code Title 17, Chapter 92, Subchapter 1, is amended to add an additional section to read as follows:

17-92-122. Compounding of therapeutic peptides.

(a) A pharmacy licensed under this chapter that complies with all applicable state and federal compounding standards may compound a therapeutic peptide, including without limitation BPC-157, ARA-290, TB-500, and GHK-Cu, when:

(1) The peptide is prescribed by a licensed physician for a specific patient;

(2) The patient is diagnosed with a serious neurological condition, terminal illness, or chronic inflammatory disease; and

(3) The active pharmaceutical ingredient is obtained from a

United States Food and Drug Administration-registered supplier and accompanied by a valid certificate of analysis.

(b) This section applies regardless of a prior placement of a therapeutic peptide on the United States Food and Drug Administration Category II list if:

(1) The federal restriction is lifted; or

(2) The compounding of the therapeutic peptide meets all safety and quality standards required by the Arkansas State Board of Pharmacy.

(c) The board may adopt rules to implement this section including without limitation required testing, labeling, and record-keeping.

SECTION 2. EFFECTIVE DATE

This act shall become effective on and after the later of the effective date of any federal action removing therapeutic peptides from United States Food and Drug Administration Category 2 restrictions, or ninety-one (91) days after passage and enactment.

Referred by Senator C. Penzo

Prepared by: JMB/JMB